How it works for academics
![circle](https://in-part-dev.com/wp-content/themes/obin-part/img/banner-circle.png)
We help academics to…
Advance research, generate impact and secure funding by partnering with industry teams around the world.
- Connect with companies from all sectors
- Help create solutions to industrial and societal challenges
- Start partnerships to scale up and validate discoveries
How academics engage through IN-PART
Respond to industrial requirements through discover
Engage with leading industry teams looking to find their next academic partners through ‘industry calls for opportunities’ and ‘requests for proposals’.
- Weekly alerts with new industry campaigns
- Companies looking for a wide range of opportunities
- A simple submission process and progress tracking through an online dashboard
Showcase your expertise to industry through connect
Increase your presence within a global community of industry teams focused on academic partnerships.
- A self-managed profile page to showcase expertise and active projects
- Proactive dissemination to engaged industry decision-makers
- Expand your network and unlock new opportunities
Find new partnerships and funding
A direct route to advance research through industry partnerships
- Personal introductions to industry teams
- Get feedback and input to support funding applications
- No success fees or hidden costs
Create impact with us
Start new collaborations
Accelerate your research
Help solve global challenges
We help academics create impact
Matching industry decision-makers with the brightest minds in academia to solve real-world problems.
Active Discover campaigns
STADA Thornton & Ross is seeking opportunities that help prevent and treat common skin conditions such as eczema, psoriasis, keratosis pilaris, acne, rosacea and seborrheic dermatitis.
AstraZeneca is seeking a higher-throughput assay to predict kidney retention of radioconjugates through in vitro cells or organoid models.
A leading rare disease company is seeking novel therapeutic approaches to treat the underlying causes of genetic kidney disease, including ADPKD and Alport syndrome.
We work with
Universities
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2022/02/01114958/UoL100px.jpg)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2022/02/01114956/UoG100px.png)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2022/02/01114955/UniversityofToronto100px.jpg)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2022/02/01114950/penn100px.png)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2022/02/01114954/UMIF100px.png)
Companies
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2016/09/11121504/pfizer.png)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2016/09/11121509/gsk.png)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2021/10/10094741/bayer-60x60.png)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2021/10/10094737/reckitt-benckiser.png)
![](https://s3.eu-west-1.amazonaws.com/in-part-dev.com-2022-20220212115132037300000001/wp-content/uploads/2021/10/10094736/Roche-logo-A80FCF9553-seeklogo.com_-90x47.png)
Testimonials
What our customers say
“IN-PART has been really useful in terms of networking and progressing our technology’s development. We are closer to market for specific applications of our technology because of the partnerships we have formed through IN-PART.”
"Discover provides us with a convenient, centralised stream of funding and collaboration opportunities, helping our team showcase our institute’s excellent research and expertise. Discover has brought his companies we would have been unlikely to engage with otherwise, and in the past six months, we have had several successes, including direct funding for research from a large pharmaceutical company."
"IN-PART is the best platform we've ever worked with! We've been subscribed since the start of 2018, and have received a range of useful introductions and feedback for our technologies from relevant companies in Europe and beyond."